Showing results (161-170 of 240) with videos related to

Sort By:
Pageof 24
Haematologica|June 11, 2010
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavengingEmanuela Messa, Sonia Carturan, Chiara Maffè, et al.
Lancet (London, England)|May 13, 2008
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II studyKatarina Le Blanc, Francesco Frassoni, Lynne Ball, et al.
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
Blood|July 9, 2008
A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantationFabio Ciceri, Myriam Labopin, Franco Aversa, et al.
Transplantation|March 20, 2013
Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignanciesVanderson Rocha, Myriam Labopin, Annalisa Ruggeri, et al.
Oncotarget|April 19, 2017
Epha3 acts as proangiogenic factor in multiple myelomaAntonella Caivano, Francesco La Rocca, Ilaria Laurenzana, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National NetworkMassimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 15, 2015
Exosomes from human mesenchymal stem cells conduct aerobic metabolism in term and preterm newborn infantsIsabella Panfoli, Silvia Ravera, Marina Podestà, et al.
Haematologica|December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibDeborah L White, Jerald Radich, Simona Soverini, et al.
Haematologica|March 7, 2007
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domainSimona Soverini, Sabrina Colarossi, Alessandra Gnani, et al.
Pageof 24